Euda Health Secures Exclusive Global Distribution Rights for Next-Gen Immune Supplement

Reuters

Aug 26

<a href="https://laohu8.com/S/EUDAW">Euda Health</a> Secures Exclusive Global Distribution Rights for Next-Gen Immune Supplement

EUDA Health Holdings Limited (NASDAQ: EUDA), a prominent non-invasive healthcare provider in Asia, has announced a new venture through its subsidiary, EUDA Health Pte. Ltd. The company has secured exclusive worldwide distribution rights for a next-generation immune health supplement from Singapore-based biotech company, Chemokine Pte. Ltd. This supplement, branded as Euda Helixé, is set to strengthen EUDA's wellness product portfolio by leveraging advanced gene activation technology. Initially targeting markets in Singapore, Malaysia, and China, EUDA aims to sell approximately 500,000 bottles within the next year. The supplement, developed with cutting-edge epigenetic technology, promises to modulate gene expression, enhance metabolism, and support longevity, thereby positioning EUDA at the forefront of molecular precision wellness.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Euda Health Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9518098-en) on August 26, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2562356277"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562356277\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562356277?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-26 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562356277","market":"fut","top_or_hot":-1,"title":"Euda Health Secures Exclusive Global Distribution Rights for Next-Gen Immune Supplement","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EUDAW\">Euda Health</a> Secures Exclusive Global Distribution Rights for Next-Gen Immune Supplement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EUDA\">EUDA Health Holdings Limited</a> (NASDAQ: EUDA), a prominent non-invasive healthcare provider in Asia, has announced a new venture through its subsidiary, EUDA Health Pte. Ltd. The company has secured exclusive worldwide distribution rights for a next-generation immune health supplement from Singapore-based biotech company, Chemokine Pte. Ltd. This supplement, branded as Euda Helixé, is set to strengthen EUDA's wellness product portfolio by leveraging advanced gene activation technology. Initially targeting markets in Singapore, Malaysia, and China, EUDA aims to sell approximately 500,000 bottles within the next year. The supplement, developed with cutting-edge epigenetic technology, promises to modulate gene expression, enhance metabolism, and support longevity, thereby positioning EUDA at the forefront of molecular precision wellness.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Euda Health Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9518098-en) on August 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Euda Health Secures Exclusive Global Distribution Rights for Next-Gen Immune Supplement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEuda Health Secures Exclusive Global Distribution Rights for Next-Gen Immune Supplement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-26 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EUDAW\">Euda Health</a> Secures Exclusive Global Distribution Rights for Next-Gen Immune Supplement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EUDA\">EUDA Health Holdings Limited</a> (NASDAQ: EUDA), a prominent non-invasive healthcare provider in Asia, has announced a new venture through its subsidiary, EUDA Health Pte. Ltd. The company has secured exclusive worldwide distribution rights for a next-generation immune health supplement from Singapore-based biotech company, Chemokine Pte. Ltd. This supplement, branded as Euda Helixé, is set to strengthen EUDA's wellness product portfolio by leveraging advanced gene activation technology. Initially targeting markets in Singapore, Malaysia, and China, EUDA aims to sell approximately 500,000 bottles within the next year. The supplement, developed with cutting-edge epigenetic technology, promises to modulate gene expression, enhance metabolism, and support longevity, thereby positioning EUDA at the forefront of molecular precision wellness.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Euda Health Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9518098-en) on August 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nNDL3svtsd:1","article_id":"2562356277","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562356277","pubTimestamp":1756209637,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"EUDA Health Holdings Limited , a prominent non-invasive healthcare provider in Asia, has announced a new venture through its subsidiary, EUDA Health Pte. Ltd. The company has secured exclusive worldwide distribution rights for a next-generation immune health supplement from Singapore-based biotech company, Chemokine Pte. Ltd. This supplement, branded as Euda Helixé, is set to strengthen EUDA's wellness product portfolio by leveraging advanced gene activation technology. Initially targeting markets in Singapore, Malaysia, and China, EUDA aims to sell approximately 500,000 bottles within the next year. The supplement, developed with cutting-edge epigenetic technology, promises to modulate gene expression, enhance metabolism, and support longevity, thereby positioning EUDA at the forefront of molecular precision wellness.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","EUDA":"EUDA Health Holdings Limited","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4196":"保健护理服务","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"Euda Health获得下一代免疫补充剂的全球独家分销权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EUDA":0.9,"NDAQ":0.9},"content_text":"Euda Health Secures Exclusive Global Distribution Rights for Next-Gen Immune Supplement\n    \n\nEUDA Health Holdings Limited (NASDAQ: EUDA), a prominent non-invasive healthcare provider in Asia, has announced a new venture through its subsidiary, EUDA Health Pte. Ltd. The company has secured exclusive worldwide distribution rights for a next-generation immune health supplement from Singapore-based biotech company, Chemokine Pte. Ltd. This supplement, branded as Euda Helixé, is set to strengthen EUDA's wellness product portfolio by leveraging advanced gene activation technology. Initially targeting markets in Singapore, Malaysia, and China, EUDA aims to sell approximately 500,000 bottles within the next year. The supplement, developed with cutting-edge epigenetic technology, promises to modulate gene expression, enhance metabolism, and support longevity, thereby positioning EUDA at the forefront of molecular precision wellness.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Euda Health Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9518098-en) on August 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}